- Home
- PIII vs BOLD Comparison
PIII vs BOLD Comparison
Compare PIII & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- BOLD
- Stock Information
- Founded
- PIII 2015
- BOLD 2018
- Country
- PIII United States
- BOLD United States
- Employees
- PIII N/A
- BOLD N/A
- Industry
- PIII Medical/Nursing Services
- BOLD
- Sector
- PIII Health Care
- BOLD
- Exchange
- PIII Nasdaq
- BOLD Nasdaq
- Market Cap
- PIII 29.3M
- BOLD 33.4M
- IPO Year
- PIII N/A
- BOLD 2024
- Fundamental
- Price
- PIII $8.73
- BOLD $1.45
- Analyst Decision
- PIII Strong Buy
- BOLD Buy
- Analyst Count
- PIII 3
- BOLD 4
- Target Price
- PIII $17.50
- BOLD $4.00
- AVG Volume (30 Days)
- PIII 3.7K
- BOLD 214.8K
- Earning Date
- PIII 11-14-2025
- BOLD 11-05-2025
- Dividend Yield
- PIII N/A
- BOLD N/A
- EPS Growth
- PIII N/A
- BOLD N/A
- EPS
- PIII N/A
- BOLD N/A
- Revenue
- PIII $1,461,823,000.00
- BOLD N/A
- Revenue This Year
- PIII N/A
- BOLD N/A
- Revenue Next Year
- PIII $10.45
- BOLD N/A
- P/E Ratio
- PIII N/A
- BOLD N/A
- Revenue Growth
- PIII 4.20
- BOLD N/A
- 52 Week Low
- PIII $5.80
- BOLD $1.00
- 52 Week High
- PIII $24.00
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- PIII 48.37
- BOLD 65.49
- Support Level
- PIII $8.60
- BOLD $1.37
- Resistance Level
- PIII $8.88
- BOLD $1.55
- Average True Range (ATR)
- PIII 0.31
- BOLD 0.09
- MACD
- PIII -0.06
- BOLD 0.01
- Stochastic Oscillator
- PIII 13.72
- BOLD 67.06
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.